Akthelia Pharmaceuticals
Modulating innate immunity to improve cancer therapy outcomes. .
Modulating innate immunity to improve cancer therapy outcomes. .
Akthelia Pharmaceuticals: Founded in 2001, Akthelia Pharmaceuticals is a biotechnology and pharmaceutical company dedicated to developing innovative antimicrobial therapeutics. With a mission to combat drug-resistant infections, the company collaborates with renowned institutions such as the Karolinska Institute in Stockholm and the University of Iceland to drive its research and product development efforts. Akthelia's diverse portfolio focuses on addressing lung and gastrointestinal infections. Their latest investment, a grant from Horizon Europe in April 2023, signifies the recognition of their groundbreaking work. As they continue to pioneer the fight against drug-resistant infections, Akthelia Pharmaceuticals is poised to make a significant impact with their novel approaches to combating antimicrobial resistance.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 |
|
17 Apr 2023 |
| Angel Round | ISK40.00M | - | 01 Sep 2019 | |
| Grant | ISK10.00M | 1 |
|
01 Mar 2013 |
| Grant | ISK10.00M | 1 |
|
01 Mar 2012 |
| Grant | ISK4.00M | 1 |
|
01 Mar 2010 |
No recent news or press coverage available for Akthelia Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
